Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 285-287

  Weiss, Timo ^a   Schönfeld, Nicolas ^a   Otto Knapp, Ralf ^a,b   Bös, Lena ^b   Bettermann, Gudrun ^a   Mauch, Harald ^a   Bauer, Torsten Thomas ^a,b   Rüssmann, Holger ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^b Deutsches Zentralkomitee Zur Bekämpfung der Tuberkulose E â Scaron V DZK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANEMIA; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BONE MARROW SUPPRESSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IN VITRO STUDY; LETTER; LOWEST INCOME GROUP; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYNEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84920588128     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00084614     Document Type: Letter

References (10)

1. Sotgiu G, Centis R, Dámbrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
2. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
3. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
4. Lee M, Lee J, Carroll MW, et al. Linezolid for the treatment of chronic extensively drug-resistant tuberculosis. N Eng J Med 2012; 367: 1508-1518.
5. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
6. Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-1507.
7. Schönfeld N, Bergmann T, Vesenbeckh S, et al. Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates. Lung India 2012; 29: 309-312.
8. Schön T, Juréen P, Chryssanthou E, et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011; 15: 502-509.
9. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51: 1431-1434.
10. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl. 2:ii17-ii25.